On the accuracy of estimation of basic pharmacokinetic parameters by the traditional noncompartmental equations and the prediction of the steady-state volume of distribution in obese patients based upon data derived from normal subjects

Journal of Pharmaceutical Sciences

Volumn 100, Issue 6, 2011, Pages 2482-2497

  Berezhkovskiy, Leonid M ^a  

^a GENENTECH INC   (United States)

Author keywords

Adipose tissue; Central elimination; Mean residence time; Obese subject; Physiologically based pharmacokinetic model; Steady state volume of distribution; Terminal volume of distribution; Tissue plasma partition coefficient; Underweight subject

Indexed keywords

DRUG;

ACCURACY; ADIPOSE TISSUE; ARTICLE; DRUG BLOOD LEVEL; HUMAN; OBESITY; PARTITION COEFFICIENT; PHYSICAL CHEMISTRY; PLASMA; PREDICTION; STEADY STATE;

EID: 79954578063     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22444     Document Type: Article

References (41)

1. ss. J Pharm Sci 96:1638-1652.
2. Berezhkovskiy LM. 2007. On the determination of the time delay in reaching the steady state drug concentration in the organ compared to plasma. J Pharm Sci 96:3432-3443.
3. Oppenheimer JH, Schwartz JL, Surks MI. 1975. Determination of common parameters of iodothyronine metabolism and distribution in man by noncompartmental analysis. J Clin Edocrinol Metab 41:319-324.
4. Benet LZ, Galeazzi RL. 1979. Noncompartmental determination of the steady-state volume of distribution. J Pharm Sci 68(8):1071-1074.
5. Nagashima R, Levy G, O'Reilly RA. 1968. Comparative pharmacokinetics of coumarin anticoagulants IV. Application of a three-compartmental model to the analysis of the dose-dependent kinetics of bishydroxycoumarin elimination. J Pharm Sci 57:1888-1895.
6. Gibaldi M, Nagashima R, Levy G. 1969. Relationship between drug concentration in plasma or serum and amount of drug in the body. J Pharm Sci 58:193-197.
7. Niazi S. 1976. Volume of distribution as a function of time. J Pharm Sci 65:452-454.
8. Berezhkovskiy LM. 2004. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci 93:1628-1640.
9. Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals, and zwitterions. J Pharm Sci 95:1238-1257.
10. Poulin P, Theil F-P. 2000. A priori prediction of the tissue/plasma partition coefficient of drugs to facilitate the use of physiologically based pharmacokinetic models in drug discovery. J Pharm Sci 89(1):16-35.
11. Poulin P, Theil F-P. 2002. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based prediction of volume of distribution. J Pharm Sci 91:129-156.
12. Berezhkovskiy LM. 2010. A valid equation for the well-stirred perfusion limited physiologically based pharmacokinetic model that consistently accounts for the blood-tissue drug distribution in the organ and the corresponding valid equation for the steady state volume of distribution. J Pharm Sci 99:475-485.
13. Nakashima E, Benet LZ. 1988. General treatment of mean residence time, clearance and volume parameters in linear mammillary models with elimination from any compartment. J Pharmacokinet Biopharm 16:475-492.
14. Wagner JG. 1976. Linear pharmacokinetic equations allowing direct calculation of many needed pharmacokinetic parameters from the coefficients and exponents of polyexponential equations which have been fitted to the data. J Pharmacokinet Biopharm 4:443-467.
15. 85Kr. J Appl Physiol 23:621-630.
16. Crandall DL, Hausman GJ, Kral JG. 1997. A review of the microcirculation of adipose tissue: Anatomic, metabolic, and angiogenic perspectives. Microcirculation 4:211-232.
17. Simcyp Population-based ADME Simulator User Manual, 2008. Turner D, Ed. Sheffield, UK: Simcyp Limited, Blades Enterprise Centre. The referred numerical values were generated by Simcyp simulator.
18. Korn GA, Korn TM. 1961. Mathematical Handbook for Scientists and Engineers, New York: McGraw- Hill, Inc.
19. Veng-Pedersen P.. 1980. Model-independent method of analyzing input in linear pharmacokinetic systems having polyexponential impulse response I: Theoretical analysis. J Pharm Sci 69(3):298-305.
20. Berezhkovskiy LM. 2008. Prediction of the possibility of the second peak of drug plasma concentration time curve after iv bolus administration from the standpoint of the traditional multi-compartmental linear pharmacokinetics. J Pharm Sci 97:2385-2393.
21. Allard S, Kinzig M, Boivin G, Sörgel F, LeBel M. 1993. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 54:368-373.
22. Pühringer FK, Keller C, Kleinsasser A, Giesinger S, Benzer A. 1999. Pharmacokinetics of rocuronium bromide in obese female patients. Eur J Anaesthesiol 16:507-510.
23. Jewesson PJ, Ensom RJ. 1985. Influence of body fat on the volume of distribution of theophylline. Ther Drug Monit 7:197-201.
24. Davis RL, Quenzer RW, Bozigian HP, Warner CW. 1990. Pharmacokinetics of ranitidine in morbidly obese women. DICP 24:1040-1043.
25. Abernethy DR, Greenblatt DJ, Divoll M, Harmatz JS, Shader RI. 1981. Alterations in drug distribution and clearance due to obesity. J Pharmacol Exp Ther 217:681-685.
26. Abernethy DR, Greenblatt DJ, Matlis R, Gugler R. 1984. Cimetidine disposition in obesity. Am J Gastroenterol 79:91-94.
27. Abernethy DR, Divoll M, Greenblatt DJ, Ameer B. 1982. Obesity, sex, and acetaminophen disposition. Clin Pharmacol Ther 31:783-790.
28. Abernethy DR, Greenblatt DJ, Divoll M, Shader RI. 1983. Enhanced glucuronide conjugation of drugs in obesity: Studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 101:873-880.
29. Abernethy DR, Greenblatt DJ. 1985. Phenytoin disposition in obesity. Determination of loading dose. Arch Neurol 42:468-471.
30. Abernethy DR, Schwartz JB. 1998. Verapamil pharmacodynamics and disposition in obese hypertensive patients. J Cardiovasc Pharmacol 11:209-215.
31. Schwartz AE, Matteo RS, Ornstein E, Young WL, Myers KJ. 1991. Pharmacokinetics of sufentanil in obese patients. Anesth Analg 73:790-793.
32. Le Jeunne C, Poirier JM, Cheymol G, Ertzbischoff O, Engel F, Hugues FC. 1991. Pharmacokinetics of intravenous bisoprolol in obese and nonobese volunteers. Eur J Clin Pharmacol 41:171-174.
33. Abernethy DR, Greenblatt DJ. 1984. Lidocaine disposition in obesity. Am J Cardiol 53:1183-1186.
34. Cheymol G, Poirier JM, Barre J, Pradalier A, Dry J. 1987. Comparative pharmacokinetics of intravenous propranolol in obese and normal volunteers. J Clin Pharmacol 27:874-879.
35. Cheymol G, Weissenburger J, Poirier JM, Gellee C. 1995. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br J Clin Pharmacol 39:684-687.
36. Servin F, Farinotti R, Haberer JP, Desmonts JM. 1993. Propofol infusion for maintenance of anesthesia in morbidly obese patients receiving nitrous oxide. A clinical and pharmacokinetic study. Anesthesiol 78:657-665.
37. Cheymol G, Poirier JM, Carrupt PA, Testa B, Weissenburger J, Levron JC, Snoeck E. 1997. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Br J Clin Pharmacol 43:563-570.
38. Jung D, Mayersohn M, Perrier D, Calkins J, Saunders R. 1982. Thiopental disposition in lean and obese patients undergoing surgery. Anesthesiology 56:269-274.
39. Weiss M.. 2008. How does obesity affect residence time dispersion and the shape of drug disposition curves? Thiopental as an example. J Pharmacokinet Pharmacodyn 35:325-336.
40. Hanley MJ, Abernethy DR, Greenblatt DJ. 2010. Effect of obesity on the pharmacokinetics of drugs in humans. Clin Pharmacokinet 49:71-87.
41. Agoram B, Woltosz WS, Bolger MB. 2001. Predicting the impact of physiological and biochemical processes on oral drug bioavailability. Adv Drug Deliv Rev 50 (Suppl 1):S41-S67.